Common irAEs associated with ICI therapy include thyroid dysfunctions, both hypothyroidism and hyperthyroidism or thyrotoxicosis, especially while administering anti-PD-1 or anti-PD-L1 antibodies. This evidence concerns the gene PDCD1 and hypothyroidism.